Ligand Pharmaceuticals Enters Into Strategic Alliance With Seelos Therapeutics

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its strategic alliance with Seelos Therapeutics, licensing them the rights to four therapeutic programs. The programs include Ligand’s aplindore program for the treatment of central nervous system disorders, a CRTH2 antagonist program for the treatment of respiratory disorders, a Captisol-enabled acetaminophen program for pain and fever management, and an H3 receptor antagonist program for the treatment of narcolepsy. Under the agreement, Ligand can receive up to $145 million milestone payments, plus royalties. Read the press release.

Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Seelos is an emerging central nervous system company that focuses on neurological and psychiatric disorders.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.